Loading patent…
AssigneesAstraZeneca AB, Shionogi & Co., Ltd.
InventorsJohn Pears, Ali Raza, Howard Hutchinson, Dennis Schneck, Takahiko Baba, Akira Touchi, Yoshitaka Yamaguchi
Estimating the term…
The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.
1-32. (canceled)
A method for reducing or avoiding adverse drug interaction in a patient in need of combination therapy, which therapy comprises the co-administration to said patient of a statin and at least one second drug that is an inducer, inhibitor or substrate of P450 isoenzyme 3A4, said method comprising administering as said statin the HMG-CoA reductase inhibitor (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof, whereby adverse interaction between said statin and said second drug through the mechanism of drug metabolism by P450 isoenzyme 3A4 is avoided.
Dependencies are inferred from the claim text.